Miglietta, Federica
Griguolo, Gaia http://orcid.org/0000-0002-8782-4509
Bottosso, Michele http://orcid.org/0000-0002-8098-1819
Giarratano, Tommaso
Lo Mele, Marcello
Fassan, Matteo http://orcid.org/0000-0001-6515-5482
Cacciatore, Matilde
Genovesi, Elisa
De Bartolo, Debora
Vernaci, Grazia http://orcid.org/0000-0003-4401-7579
Amato, Ottavia http://orcid.org/0000-0002-3690-8542
Porra, Francesca
Conte, PierFranco
Guarneri, Valentina http://orcid.org/0000-0002-2375-8397
Dieci, Maria Vittoria http://orcid.org/0000-0002-3967-9861
Funding for this research was provided by:
Università degli Studi di Padova (BIRD 2019, BIRD 2020, BIRD 2020, BIRD-2019, BIRD 2019, BIRD 2020, DOR-2194859/21)
Associazione Italiana per la Ricerca sul Cancro (5 per mille ID. 22759 program, 5 per mille ID. 22759 program)
Article History
Received: 11 November 2021
Accepted: 14 April 2022
First Online: 20 May 2022
Competing interests
: F.M. reports personal fee from Roche outside the submitted work. M.F. received honoraria for consulting, advisory role, speaker bureau, and/or research funding from Astellas Pharma, QED Therapeutics, Diaceutics, Tesaro, Roche, Eli Lilly, and Novartis, all outside the submitted work. P.F.C. reports personal fees from Novartis, EliLilly, AstraZeneca, Tesaro, BMS, Roche, all outside the submitted work. V.G.: reports personal fees from Roche, Novartis, Eli Lilly, MSD outside the submitted work. M.V.D. reports personal fees from Lilly, Genomic Health, Novartis and Celgene, all outside the submitted work. All remaining authors have declared no conflicts of interest.